Literature DB >> 15534086

Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.

Fredrik Wiklund1, Björn-Anders Jonsson, Anthony J Brookes, Linda Strömqvist, Jan Adolfsson, Monica Emanuelsson, Hans-Olov Adami, Katarina Augustsson-Bälter, Henrik Grönberg.   

Abstract

PURPOSE: The RNASEL gene has been proposed as a candidate gene for the HPC1 locus through a positional cloning and candidate gene approach. Cosegregation between the truncating mutation E265X and disease in a hereditary prostate cancer (HPC) family and association between prostate cancer risk and the common missense variant R462Q has been reported. To additionally evaluate the possible role of RNASEL in susceptibility to prostate cancer risk, we performed a comprehensive genetic analysis of sequence variants in RNASEL in the Swedish population. EXPERIMENTAL
DESIGN: Using 1624 prostate cancer cases and 801 unaffected controls, the truncating mutation E265X and five common sequence variants, including the two missense mutations R462Q and D541E, were evaluated for association between genotypes/haplotypes and prostate cancer risk.
RESULTS: The prevalence of E265X carriers among unaffected controls and prostate cancer patients was almost identical (1.9 and 1.8% in controls and cases, respectively), and evidence for segregation of E265X with disease was not observed within any HPC family. Overall, the analyses of common sequence variants provided limited evidence for association with prostate cancer risk. We found a marginally significant inverse association between the missense mutation D541E and sporadic prostate cancer risk (odds ratio, 0.77; 95% confidence interval, 0.59-1.00) and reduced risk of prostate cancer in carriers of two different haplotypes being completely discordant.
CONCLUSIONS: Considering the high quality in genotyping and the size of this study, these results provide solid evidence against a major role of RNASEL in prostate cancer etiology in Sweden.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534086     DOI: 10.1158/1078-0432.CCR-04-0982

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

1.  The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel.

Authors:  Efrat Dagan; Yael Laitman; Nurit Levanon; Avner Feuer; Ami A Sidi; Jack Baniel; Yaacov Korach; Gilad Ben Baruch; Eitan Friedman; Ruth Gershoni-Baruch
Journal:  Fam Cancer       Date:  2006-08-31       Impact factor: 2.375

2.  A new human retrovirus associated with prostate cancer.

Authors:  Hung Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-23       Impact factor: 11.205

3.  An update analysis of two polymorphisms in encoding ribonuclease L gene and prostate cancer risk: involving 13,372 cases and 11,953 controls.

Authors:  Yuan-Yuan Mi; Li-Jie Zhu; Sheng Wu; Ning-Han Feng
Journal:  Genes Nutr       Date:  2011-04-17       Impact factor: 5.523

Review 4.  A scientific journey through the 2-5A/RNase L system.

Authors:  Robert H Silverman
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

5.  RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis.

Authors:  Bingbing Wei; Zhuoqun Xu; Jun Ruan; Ming Zhu; Ke Jin; Deqi Zhou; Zhiqiang Yan; Feng Xuan; Hongyi Zhou; Xing Huang; Jian Zhang; Peng Lu; Jianfeng Shao
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

6.  Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.

Authors:  Megan D Fesinmeyer; Erika M Kwon; Rong Fu; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2011-02-25       Impact factor: 4.104

7.  RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies.

Authors:  Li-Feng Zhang; Yuan-Yuan Mi; Chao Qin; Yong Wang; Qiang Cao; Jun-Feng Wei; Yao-Jun Zhou; Ning-Han Feng; Wei Zhang
Journal:  Mol Biol Rep       Date:  2011-01-09       Impact factor: 2.316

8.  A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.

Authors:  Jonathan D Schoenfeld; Danielle N Margalit; Julie L Kasperzyk; Irene M Shui; Jennifer R Rider; Mara M Epstein; Allison Meisner; Stacey A Kenfield; Neil E Martin; Paul L Nguyen; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

9.  Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.

Authors:  Christiane M Robbins; Wenndy Hernandez; Chiledum Ahaghotu; James Bennett; Gerald Hoke; Terry Mason; Curtis A Pettaway; Srinivasan Vijayakumar; Sally Weinrich; Paulette Furbert-Harris; Georgia Dunston; Isaac J Powell; John D Carpten; Rick A Kittles
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

10.  Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.

Authors:  Sanggu Kim; Namshin Kim; Beihua Dong; David Boren; Serena A Lee; Jaydip Das Gupta; Christina Gaughan; Eric A Klein; Christopher Lee; Robert H Silverman; Samson A Chow
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.